KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect KALA BIO to announce earnings of ($6.00) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

KALA BIO (NASDAQ:KALA) last released its earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($8.50) by $8.36.

KALA BIO Stock Performance

Shares of NASDAQ:KALA opened at $0.78 on Tuesday. The stock has a market capitalization of $15.14 million, a price-to-earnings ratio of -0.01 and a beta of -2.26. KALA BIO has a 1-year low of $0.59 and a 1-year high of $1,030.00. The company has a 50 day moving average price of $1.82 and a 200 day moving average price of $9.96.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KALA. Wall Street Zen downgraded KALA BIO from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of KALA BIO in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $1,158.33.

Institutional Trading of KALA BIO

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after purchasing an additional 1,534 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of KALA BIO in the second quarter worth $62,000. Virtu Financial LLC purchased a new position in shares of KALA BIO during the fourth quarter valued at $48,000. Jane Street Group LLC purchased a new position in shares of KALA BIO during the fourth quarter valued at $80,000. Finally, Woodline Partners LP purchased a new position in shares of KALA BIO during the first quarter valued at $1,483,000. 24.61% of the stock is owned by hedge funds and other institutional investors.

About KALA BIO

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.